Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution

Wednesday, April 23, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

MUNDELEIN, Ill., April 22 Sysmex America, Inc. todayannounced the successful completion of Mercy Medical Center's (Canton, OH)beta studies for its integrated hematology and A1C automation solution. Thisfirst-of-kind solution, which combines the Sysmex HST-N hematology automationplatform and the Bio-Rad Laboratories, Inc. VARIANT(TM) II TURBO Link,enables on-demand, automated diabetes testing in a random access setting."This integrated testing solution, now fully on-line at Mercy, also utilizesautomated decision logic rules software, Sysmex MOLIS WAM(TM), to maximizeefficiencies in the area of data and sample management and labor utilization,"said Barbara Carter, Coordinator Automated/Core Laboratory, Mercy MedicalCenter. Mercy Medical Center's early adoption of the integrated hematology andA1C Testing Solution aligns with the hospital's impressive list of world,national, state and Stark county's "firsts." The hospital is jointly owned andoperated by the Sisters of Charity Health System and University HospitalsHealth System. This integrated testing Solution will be available to hospitalsacross the nation beginning the end of April 2008.

"As an early adopter of the automated A1C Testing Solution, we areproviding superior diabetes testing services that positively impact thequality and timeliness of the acute care and management of diabetic patients.With diabetes affecting over 20 million children and adults in the UnitedStates, coupled with the nation's obesity epidemic, we saw the need to createa laboratory infrastructure for the future," said Mary Ann Burich-Boccia,Administrative Director, Laboratory, Mercy Medical Center. "By automating andconsolidating our high volume hematology and diabetes testing, we havedramatically improved our operational efficiency while reducing costs anderrors. And, with seventy-five percent of our samples no longer needingtechnologist-touch, we are freeing our technologists for more critical taskssuch as abnormal patient result review," she added.

Mercy Medical Center's integrated testing solution includes the SysmexHST-302 automated platform -- two XE-Series automated hematology analyzers,one SP-1000i automated slide maker and stainer, MOLIS WAM, one TS-500 TubeSorter/archiver, Return Line and the Bio-Rad VARIANT II TURBO Link A1C testingsystem. "Our A1C method uses HPLC technology, the industry's gold standard forA1C testing. In addition to diabetes monitoring, our method detects somecommon hemoglobin abnormalities. This clinical information can be forwarded tothe physician, adding valuable patient information," said Scott Joksch, SeniorProduct Manager at Bio-Rad.

"In addition to enhancing its diabetic testing services, Mercy MedicalCenter's foresight has enabled the automation of testing and data managementof 90% of tests performed on EDTA samples and automated sample management ofvirtually 100% of all EDTA samples (i.e. CBC, Diff, Retic, ESR and otheresoteric tests)," said Nilam Patel, Sr. Product Manager, Automation Solutions,Sysmex America, Inc. "This Lavender Top Management(TM) solution by Sysmexoffers clinical laboratories quality results, superior instrument andautomation performance (uptime) and improved productivity, turn around timesand labor utilization," added Patel.

About HbA1c

The hemoglobin A1c (A1C) blood test, which measures the amount of glucoseattached to the hemoglobin in the red blood cell, is an estimate of apatient's blood glucose control during the previous three to four months.

Diabetes is a chronic condition that can increase a patient's risk fordeveloping serious complications including heart disease and stroke, highblood pressure, blindness, kidney and nervous system diseases. Proper diabetesmanagement can delay or even prevent the onset of complications, allowingpatients to live healthier, more productive lives.

About Mercy Medical Center


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store